Science and Legal Advisors

Science and Legal Advisors

Howard H. Bailey

Dr. Bailey is Interim Director of the University of Wisconsin Carbone Cancer Center and Professor of Medicine at the University of Wisconsin School of Medicine and Public Health. He is the principal investigator on most of the initial oral POH trials from the University of Wisconsin and has a research focus in anti-cancer drug development, especially chemoprevention. Dr. Bailey is the University’s expert on drug and nutrient development for the prevention or treatment of cancer and a national expert on chemoprevention.
MD

Marc B. Chamberlain

Dr. Chamberlain is Professor of Neurology at the University of Washington, Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. He is a world-renowned neuro-oncologist who is known for his work on leptomeningeal carcinomatosis. Dr. Chamberlain developed many of the methods used today in evaluating and managing neoplastic meningitis, and has increasingly focused on clinical trials for primary brain tumors.
MD

Steven L. Gianotta

Dr. Giannotta is Professor and Chairman of the Department of Neurological Surgery at the University of Southern California. He is internationally recognized for his clinical interests in vascular and skull base surgery. Dr. Giannotta has an interest and special expertise in surgical approaches to the cranial base and is considering POH for use in treatment of skull base tumors.
MD

Michael N. Gould

Dr. Gould is Professor of Medicine at the University of Wisconsin, and the investigator who initiated studies of POH as an anti-cancer agent. His laboratory is seeking the molecular basis that causes monoterpenes to selectively induce apoptosis and inhibit proliferation in cancer cells by investigating the effects of those drugs on cell cycle associated protein and signaling pathways.
Ph.D

Daniel Levin

Dr. Levin is President and R&D Director of Norac Pharma, and has helped in developing, manufacturing and testing POH formulations. He has extensive experience in pharmaceutical process R&D and manufacturing in Europe, Canada, the United States, and India, working with ICI, Zeneca, AstraZeneca, Avecia, Torcan, and Piramal Healthcare, prior to Norac Pharma.
Ph.D, CCHEM, FRSC

Victor A. Levin

Dr. Levin is considered the Father of American neuro-oncology with an illustrious career as an oncologist at the University of California, San Francisco and the University of Texas MD Anderson Cancer Center. He was founder and first president of the Society of Neuro-Oncology and founder of Orbus Therapeutics, Inc. He currently is part of the KP Redwood City Hospital Department of Neurosurgery, doing clinical neuro-oncology with an emphasis on primary malignant brain tumors.
MD

David M. Peereboom

Dr. Peereboom is a medical oncologist specializing in the management of brain tumors, with an active practice at the Cleveland Clinic. His specialty interests are in neuro-oncology and experimental therapeutics, and he’s a prominent member of the Society of Neuro-Oncology. Dr. Peereboom was involved in some of the initial oral POH studies.
MD

Michael D. Prados

Dr. Prados is Director of the Department of Translational Research at the University of California, San Francisco. He has over 20 years of experience at UCSF in treating and supervising the treatment of adults and children who have brain tumors. The National Cancer Institute’s Adult Brain Tumor Consortium, which sponsors trials of treatment regimens for brain tumors, is based at UCSF under Dr. Prados’ leadership. He is also principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is one of seven institutions in the United States participating in this NIH-funded cooperative effort to develop effective new strategies for treating children with malignant brain tumors.
MD

Vincent Simmon

Dr. Simmon has over 30 years of experience growing biotechnology companies and developing products in the biotechnology industry. Dr. Simmon has served as a Governor of the Emerging Companies Section of BIO (Biotechnology Industrial Organization) and as a director of the Chemical Industries Institute for Toxicology (Research Triangle Park). He has been CEO, COO, and/or a director of public and private biotechnology companies since 1990, including Alpha 1 Biomedicals, Cortex Pharmaceuticals, Merrimack Pharmaceuticals, and Xytis, Inc. Currently he is a member of the board of directors of Innovative NeuroTechnologies, Personalized Pharmaceuticals Systems, and Thuris Corporation. He has personally supervised the submission and acceptance of more than ten INDs.
Ph.D, VP, Chief Regulatory Officer

Michael A. Davitz

Dr. Davitz is both a medical doctor and a patent lawyer. Prior to starting his practice in patent law, Dr. Davitz was an assistant professor in pathology. He has been able to effectively combine his knowledge of medicine and law into a thriving patent law practice as a partner of Axinn,Veltrop. He is the key advisor for NTI’s patent strategy.
MD, JD

Patrick Y. Wen

Dr. Wen is Director of Cancer Neurology at Brigham and Women’s Hospital, Director of Dana-Farber/Brigham and Women’s Cancer Center Neuro-Oncology Disease Center, and Professor of Neurology, Harvard Medical School. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. Another of his clinical interests is neurologic complications of cancer.
MD

Comments are closed.